AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden · Delayed Price · Currency is SEK 1.470
+0.090 (6.52%)
Apr 30, 2026, 12:06 PM CET
AlzeCure Pharma AB Earnings Call Transcripts
Fiscal Year 2025
-
Orphan drugs are a rapidly growing, high-value segment, driven by unmet needs and strong incentives. ACD 440, a topical TRPV1 antagonist, targets erythromelalgia—a rare, severe pain disorder—with promising clinical results and orphan designation, positioning it for out-licensing and global commercialization.
Fiscal Year 2024
-
ACD440, a topical TRPV1 antagonist gel, has shown significant pain reduction and strong safety in phase Ib and IIa studies for neuropathic pain with thermal hypersensitivity. The product offers local, predictable relief, can be combined with other treatments, and targets a large, growing market with high unmet need.